Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Clinical trial NCT01726517 · COMPLETED

Trial details

NCT number: NCT01726517
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Hepatitis C Virus

Start date: 2012-10-01
Primary completion: 2013-07-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.